PolyVascular, a pioneering medtech company focused on developing innovative transcatheter valve solutions for children with congenital heart disease, is proud to announce its acceptance to present at the prestigious Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference, hosted by the Cardiovascular Research Foundation (CRF). The conference, which is the world’s foremost educational forum specializing in interventional cardiovascular medicine, will take place from October 27-30, 2024, at the Walter E. Washington Convention Center in Washington, D.C.

PolyVascular will present its latest preclinical study, “In Vivo Chronic Performance of a Novel Pediatric-Sized Polymeric Transcatheter Pulmonary Valve,” which underscores the company’s commitment to advancing pediatric cardiology valve technology through minimally invasive interventions. The study’s findings offer a promising path to first-in-human studies and exemplify PolyVascular’s success towards developing the first polymeric transcatheter pulmonary valve designed specifically for small children.

Dr. Henri Justino, Co-Founder; Cindy Clague, Vice President of Research and Development; and Katie Bales, Vice President of Investor Relations will be representing PolyVascular at the conference. They will join global leaders in interventional cardiology to share insights and foster collaboration in the quest to advance cardiovascular care.

The TCT 2024 conference, celebrating its 36th edition, continues to be a dynamic platform for igniting innovation, education, and connection among top clinicians, researchers, and industry experts. This year’s program emphasizes the integration of cutting-edge interventions with preventive strategies to revolutionize the field of cardiovascular care and improve patient outcomes.